Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 24, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Efinaconazole Topical Solution, 10%".
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 2.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alembic Pharmaceuticals has received final approval from the USFDA for its generic version of Efinaconazole Topical Solution, 10%, used to treat toenail fungal infections. The approval is therapeutically equivalent to Bausch Health's brand Jublia. Alembic was among the first companies to file this generic with a Paragraph IV patent challenge, which could give it 180 days of marketing exclusivity in the US. The reference product has an estimated US market size of around US$ 500 million (12 months ending December 2025, per IQVIA). With this, Alembic's cumulative ANDA tally from USFDA rises to 234 (215 final + 19 tentative).
Positive for the stock — the approval opens up access to a sizeable US$500M addressable market, and Paragraph IV status may allow Alembic to capture early share with potential exclusivity benefits, supporting future US revenue growth.